チソツマブ ベドチン（遺伝子組換え） 化學(xué)特性,用途語(yǔ),生産方法
合成
Tisotumab vedotin is present in a 4:1 linker-drug carrier to antibody ratio and may be synthesized in a manner similar to other ADCs using vedotin, such as Adcetris, Polivy, and Padcev. In these synthetic methods, the thiol group in 31.2 is exposed by reduction of the antibody disulfide bonds mediated by TCEP or DTT. Subsequently, the thiol group in 31.2 reacts with the maleimide linker functional group in 31.3 to generate Tisotumab vedotin 31, and any unreacted linker-drug carrier is quenched by using excess N-acetylcysteine.
チソツマブ ベドチン（遺伝子組換え） 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品